T1	Pregnancy_considerations 0 100	Female subjects who are pregnant or breast-feeding or considering becoming pregnant during the study
T2	Person 111 115	aged
T3	Value 116 132	<18 years of age
R1	Has_value Arg1:T2 Arg2:T3	
T4	Non-query-able 134 176	Patients who cannot give informed consent,
T5	Pregnancy_considerations 178 252	Pregnant patients or those who are breastfeeding will be deemed ineligible
T6	Drug 280 294	anti-TNF agent
T7	Procedure 261 270	treatment
T8	Temporal 255 260	Prior
R2	Has_temporal Arg1:T7 Arg2:T8	
R3	AND Arg1:T7 Arg2:T6	
T9	Condition 296 313	Contra-indication
T10	Drug 324 327	GLM
T11	Condition 329 345	Hypersensitivity
T12	Drug 353 369	active substance
T13	Drug 387 397	excipients
*	OR T12 T13
T14	Scope 353 397	active substance or to any of the excipients
R4	Has_scope Arg1:T11 Arg2:T14	
T15	Condition 406 423	tuberculosis (TB)
T16	Temporal 399 405	Active
R5	Has_temporal Arg1:T15 Arg2:T16	
T17	Qualifier 425 430	acute
T18	Qualifier 434 441	chronic
T19	Condition 442 463	Hepatitis B infection
*	OR T17 T18
T20	Scope 425 441	acute or chronic
R6	Has_scope Arg1:T19 Arg2:T20	
T21	Condition 473 490	severe infections
T22	Condition 499 505	sepsis
T23	Condition 513 537	opportunistic infections
T24	Condition 548 561	HIV infection
R7	Subsumes Arg1:T23 Arg2:T24	
R8	Subsumes Arg1:T21 Arg2:T22	
*	OR T21 T23 T19 T15 T11 T27
T25	Qualifier 563 571	Moderate
T26	Qualifier 575 581	severe
*	OR T26 T25
T27	Condition 582 595	heart failure
T28	Measurement 597 601	NYHA
T29	Value 602 614	class III/IV
R9	Has_value Arg1:T28 Arg2:T29	
T30	Scope 563 581	Moderate or severe
R10	Subsumes Arg1:T30 Arg2:T28	
R11	Has_scope Arg1:T27 Arg2:T30	
T31	Scope 329 614	Hypersensitivity to the active substance or to any of the excipients; Active tuberculosis (TB), acute or chronic Hepatitis B infection or other severe infections such as sepsis and/or opportunistic infections including HIV infection; Moderate or severe heart failure (NYHA class III/IV
R12	AND Arg1:T9 Arg2:T10	
T32	Scope 296 327	Contra-indication to use of GLM
R13	Subsumes Arg1:T32 Arg2:T31	
T33	Qualifier 672 678	latent
T34	Qualifier 662 668	active
T35	Temporal 654 661	current
*	OR T33 T34
R14	Has_temporal Arg1:T34 Arg2:T35	
T36	Condition 679 681	TB
T37	Scope 654 677	current active or laten
R15	Has_scope Arg1:T36 Arg2:T37	
T38	Observation 687 702	medical history
T39	Procedure 704 724	physical examination
T40	Procedure 732 748	chest radiograph
T41	Measurement 762 843	Mycobacterium tuberculosis antigen-specific interferon-gamma release assay (IGRA)
T42	Value 753 761	positive
R16	Has_value Arg1:T41 Arg2:T42	
*	OR T40 T39 T38
T43	Scope 687 748	medical history, physical examination and/or chest radiograph
R17	AND Arg1:T43 Arg2:T36	
*	OR T43 T41
T44	Procedure 922 946	gastrointestinal surgery
T45	Temporal 947 979	within 2 months before screening
R18	Has_temporal Arg1:T44 Arg2:T45	
T46	Procedure 898 907	colectomy
T47	Mood 879 896	imminent risk for
T48	Observation 861 871	history of
*	OR T47 T48
T49	Scope 861 896	history of, or at imminent risk for
R19	Has_scope Arg1:T46 Arg2:T49	
T50	Condition 993 1018	colonic mucosal dysplasia
T51	Condition 1022 1048	adenomatous colonic polyps
T52	Procedure 1063 1070	removed
T53	Negation 1059 1062	not
R20	Has_negation Arg1:T52 Arg2:T53	
*	OR T51 T50
R21	AND Arg1:T51 Arg2:T52	
T54	Procedure 1082 1093	stool study
T55	Value 1094 1102	positive
T56	Qualifier 1107 1124	enteric pathogens
T57	Qualifier 1128 1155	Clostridium difficile toxin
*	OR T56 T57
T58	Scope 1107 1155	enteric pathogens or Clostridium difficile toxin
R22	Has_scope Arg1:T55 Arg2:T58	
R23	Has_value Arg1:T54 Arg2:T55	
T59	Drug 1158 1178	Oral corticosteroids
T60	Multiplier 1189 1206;1225 1232	>40 mg prednisone per day
R24	Has_multiplier Arg1:T59 Arg2:T60	
T61	Drug 1245 1257	cyclosporine
T62	Drug 1259 1269	tacrolimus
T63	Drug 1271 1280	sirolimus
T64	Drug 1285 1306	mycophenolate mofetil
T65	Temporal 1307 1360	within 8 weeks before the first study agent injection
*	OR T64 T63 T62 T61
T66	Scope 1245 1306	cyclosporine, tacrolimus, sirolimus, or mycophenolate mofetil
R25	Has_temporal Arg1:T66 Arg2:T65	
T67	Drug 1375 1396	investigational agent
T68	Temporal 1397 1416	within 5 half-lives
R26	Has_temporal Arg1:T67 Arg2:T68	
T69	Temporal 1431 1469	before the first study agent injection
R27	Has_temporal Arg1:T67 Arg2:T69	
*	OR T67 T66 T59
T70	Drug 1502 1519	live vaccinations
T71	Temporal 1520 1553	within 4 weeks prior to enrolment
R28	Has_temporal Arg1:T70 Arg2:T71	
